{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T17:21:00Z","timestamp":1788283260079,"version":"build-2803163510"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:p>We describe 6 pediatric patients (12 to 18\u2009y) with relapsed or refractory Hodgkin lymphoma treated with consolidative Brentuximab vedotin (Bv) following reinduction chemotherapy and autologous stem cell transplantation. The progression-free survival after autologous stem cell transplantation was 12, 18, 22, 24, 30, and 30 months. Most patients tolerated Bv well although 2 patients developed grade 3 neuropathy that prevent them from completing the scheduled 16 doses of Bv. Consolidative Bv in children and adolescents, as currently recommended for adult patients with early relapsed or refractory Hodgkin lymphoma, is feasible but with some significant toxicities.<\/jats:p>","DOI":"10.1097\/mph.0000000000001703","type":"journal-article","created":{"date-parts":[[2019,12,24]],"date-time":"2019-12-24T14:14:03Z","timestamp":1577196843000},"page":"e191-e194","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Brentuximab Vedotin as Consolidation Therapy After Autologous Stem Cell Transplantation in Children and Adolescents (&lt;18\u2009y) With Early Relapse Hodgkin Lymphoma"],"prefix":"10.1097","volume":"43","author":[{"given":"Karen S.","family":"Fern\u00e1ndez","sequence":"first","affiliation":[{"name":"Pediatric Hematology\/Oncology, Cancer and Blood Disorders Center, Valley Children\u2019s Hospital, Madera"},{"name":"Stanford University, School of Medicine, Palo Alto, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Mavers","sequence":"additional","affiliation":[{"name":"Division of Stem Cell Transplantation and Regenerative Medicine"},{"name":"Stanford University, School of Medicine, Palo Alto, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianna J.","family":"Marks","sequence":"additional","affiliation":[{"name":"Pediatric Hematology\/Oncology, Lucile Packard Children\u2019s Hospital"},{"name":"Stanford University, School of Medicine, Palo Alto, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajni","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Division of Stem Cell Transplantation and Regenerative Medicine"},{"name":"Stanford University, School of Medicine, Palo Alto, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,2,18]]},"reference":[{"key":"R1-20260901","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1182\/blood-2015-07-641035","article-title":"Hodgkin lymphoma in children and adolescents: improving the therapeutic index","volume":"126","author":"Kelly","year":"2015","journal-title":"Blood"},{"key":"R2-20260901","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/0140-6736(93)92411-L","article-title":"Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin\u2019s disease: results of a BNLI randomised trial","volume":"341","author":"Linch","year":"1993","journal-title":"Lancet"},{"key":"R3-20260901","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","article-title":"Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin\u2019s disease: a randomised trial","volume":"359","author":"Schmitz","year":"2002","journal-title":"Lancet"},{"key":"R4-20260901","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1038\/bmt.2015.177","article-title":"A prognostic model predicting autologous transplantation outcomes in children, adolescents and young adults with Hodgkin lymphoma","volume":"50","author":"Satwani","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"R5-20260901","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.bbmt.2014.10.020","article-title":"Improved outcomes after autologous bone marrow transplantation for children with relapsed or refractory Hodgkin lymphoma: twenty years experience at a single institution","volume":"21","author":"Garfin","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"R6-20260901","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","article-title":"Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin\u2019s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"385","author":"Moskowitz","year":"2015","journal-title":"Lancet"},{"key":"R7-20260901","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1182\/blood-2018-07-861641","article-title":"Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse","volume":"132","author":"Moskowitz","year":"2018","journal-title":"Blood"},{"key":"R8-20260901","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1200\/JCO.2004.02.121","article-title":"High-dose therapy and autologous hematopoietic stem-cell transplantation for recurrent or refractory pediatric Hodgkin\u2019s disease: results and prognostic indices","volume":"22","author":"Lieskovsky","year":"2004","journal-title":"J Clin Oncol"},{"key":"R9-20260901","doi-asserted-by":"crossref","first-page":"e450","DOI":"10.1016\/S2352-3026(18)30153-4","article-title":"Brentuximab vedotin for paediatric relapsed or refractory Hodgkin\u2019s lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1\/2 study","volume":"5","author":"Locatelli","year":"2018","journal-title":"Lancet Haematol"},{"key":"R10-20260901","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/S1470-2045(18)30426-1","article-title":"Brentuximab vedotin with gemcitabine for paediatric and young adult patients with relapsed or refractory Hodgkin\u2019s lymphoma (AHOD1221): a Children\u2019s Oncology Group, multicentre single-arm, phase 1-2 trial","volume":"19","author":"Cole","year":"2018","journal-title":"Lancet Oncol"},{"issue":"suppl","key":"R11-20260901","doi-asserted-by":"crossref","first-page":"e19012","DOI":"10.1200\/JCO.2019.37.15_suppl.e19012","article-title":"Feasibility of brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in children and adolescents (<18 years) with early relapse Hodgkin lymphoma","volume":"2019","author":"Fern\u00e1ndez","year":"2019","journal-title":"J Clin Oncol"},{"key":"R12-20260901","doi-asserted-by":"crossref","first-page":"e27962","DOI":"10.1002\/pbc.27962","article-title":"Brentuximab vedotin as consolidation after hematopoietic cell transplant for relapsed Hodgkin lymphoma in pediatric patients","volume":"66","author":"Flerlage","year":"2019","journal-title":"Pediatr Blood Cancer"},{"key":"R13-20260901","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1001\/jamaoncol.2018.6278","article-title":"Maintenance therapies for Hodgkin and non-Hodgkin lymphomas after autologous transplantation: a consensus project of ASBMT, CIBMTR, and the Lymphoma Working Party of EBMT","volume":"5","author":"Kanate","year":"2019","journal-title":"JAMA Oncol"},{"key":"R14-20260901","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1365-2141.2008.07146.x","article-title":"Combination of the anti-CD30-auristatin-E antibody-drug conjugate (SGN-35) with chemotherapy improves antitumour activity in Hodgkin lymphoma","volume":"142","author":"Oflazoglu","year":"2008","journal-title":"Br J Haematol"},{"key":"R15-20260901","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1200\/JCO.2008.20.3778","article-title":"Phase II study of weekly gemcitabine and vinorelbine for children with recurrent or refractory Hodgkin\u2019s disease: a children\u2019s oncology group report","volume":"27","author":"Cole","year":"2009","journal-title":"J Clin Oncol"},{"key":"R16-20260901","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/bjh.13388","article-title":"A phase 2 study of bortezomib in combination with ifosfamide\/vinorelbine in paediatric patients and young adults with refractory\/recurrent Hodgkin lymphoma: a Children\u2019s Oncology Group study","volume":"170","author":"Horton","year":"2015","journal-title":"Br J Haematol"},{"key":"R17-20260901","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1002\/pbc.25205","article-title":"Ifosfamide and vinorelbine is an effective reinduction regimen in children with refractory\/relapsed Hodgkin lymphoma, AHOD00P1: a Children\u2019s Oncology Group report","volume":"62","author":"Trippett","year":"2015","journal-title":"Pediatr Blood Cancer"},{"issue":"suppl","key":"R18-20260901","doi-asserted-by":"crossref","first-page":"P2.6-015","DOI":"10.1212\/WNL.92.15_supplement.P2.6-015","article-title":"Chronic inflammatory demyelinating polyneuropahty (CIDP) manifesting in the course of treatment of Hodgkin\u2019s lymphoma with brentuximab","volume":"92","author":"Frey","year":"2019","journal-title":"Neurology"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MPH.0000000000001703","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T17:03:51Z","timestamp":1788282231000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MPH.0000000000001703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,18]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000001703","relation":{},"ISSN":["1077-4114","1536-3678"],"issn-type":[{"value":"1077-4114","type":"print"},{"value":"1536-3678","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,18]]},"assertion":[{"value":"2019-10-07","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-01","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}